Dr. Fajgenbaum’s experience with Castleman disease led him to discover that FDA-approved drugs can be repurposed to treat other diseases, often with remarkable success. He highlights cases like aspirin reducing cancer recurrence, lidocaine lowering breast cancer mortality, and colchicine preventing heart attacks—applications overlooked due to financial and systemic barriers. Through his nonprofit Every Cure, he uses AI and biomedical databases to systematically match existing drugs to new diseases, accelerating discovery without the cost and delay of traditional drug development. He emphasizes patient empowerment, urging individuals to engage with disease organizations and question standard care. His work underscores the importance of collaboration, physician education, and public involvement in unlocking hidden treatments. While repurposed drugs like rapamycin show promise for longevity and prevention, he cautions against unproven use without evidence. Ultimately, Fajgenbaum advocates for a shift in medical mindset—one that values curiosity, resilience, and proactive exploration of existing therapies to transform outcomes for rare and untreatable conditions.